At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in TCAR procedures, doubling the platform's U.S. addressable market to ~75,000 annual carotid stenting procedures. The approval was supported by the CGUARDIANS II trial showing 100% acute device success and zero adverse events at 30 days. This is a significant commercial milestone for the company, which has a $36M market cap and had been limited to CAS procedures.
- FDA approved PMA Supplement for CGuard Prime TransCarotid Stent System for TCAR procedures
- Approval doubles total addressable U.S. market to ~75,000 annual carotid stenting procedures (TCAR + CAS)
- CGUARDIANS II trial: 100% acute device success, zero deaths/strokes/MI/stent thrombosis at 30 days
- Over 35,000 TCAR procedures performed annually in the U.S.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access